An early blood test can predict survival in patients with metastatic prostate cancer

A blood test, performed when metastatic prostate cancer is first diagnosed, can predict which patients are likely to respond to treatment and survive the longest. It can help providers decide which patients should receive standard treatment versus who might stand to benefit from riskier, more aggressive new drug trials.

from Latest Science News -- ScienceDaily https://ift.tt/0Jrlhxv